The expression of VEGFR2 might be a prognostic factor for gastric cancer, and the blockage of VEGFR2 in metastatic gastric cancers that progressed after fluoropyrimidine-based or platinum-based first-line chemotherapy has shown a survival benefit as a second-line treatment option9,10. This evidence concerns the gene KDR and gastric cancer.